

Clinical course, therapeutic responses and outcomes in antibody-associated demyelination

Journal of Neurology, Neurosurgery and Psychiatry
89, 127-137

DOI: [10.1136/jnnp-2017-316880](https://doi.org/10.1136/jnnp-2017-316880)

Citation Report

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Defining distinct features of anti-MOG antibody associated central nervous system demyelination. <i>Therapeutic Advances in Neurological Disorders</i> , 2018, 11, 175628641876208. | 1.5 | 137 |
| 2 | Paediatric acute disseminated encephalomyelitis followed by optic neuritis: disease course, treatment response and outcome. <i>European Journal of Neurology</i> , 2018, 25, 782-786. | 1.7 | 45 |
| 4 | Clinical course of MOG antibody-associated recurrent demyelinating diseases. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 118-118. | 0.9 | 4 |
| 5 | Diagnosis and Treatment of NMO Spectrum Disorder and MOG-Encephalomyelitis. <i>Frontiers in Neurology</i> , 2018, 9, 888. | 1.1 | 194 |
| 6 | Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disorders: Toward a New Spectrum of Inflammatory Demyelinating CNS Disorders?. <i>Frontiers in Immunology</i> , 2018, 9, 2753. | 2.2 | 49 |
| 7 | Anti-Myelin Oligodendrocyte Glycoprotein and Human Leukocyte Antigens as Markers in Pediatric and Adolescent Multiple Sclerosis: on Diagnosis, Clinical Phenotypes, and Therapeutic Responses. <i>Multiple Sclerosis International</i> , 2018, 2018, 1-9. | 0.4 | 9 |
| 8 | Rebound of relapses after discontinuation of rituximab in a patient with MOG-IgG1 positive highly relapsing optic neuritis: a case report. <i>BMC Neurology</i> , 2018, 18, 216. | 0.8 | 8 |
| 10 | Clinical utility of anti-MOG antibody testing in a Danish cohort. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 26, 61-67. | 0.9 | 10 |
| 11 | Pediatric Multiple Sclerosis: an Update. <i>Current Neurology and Neuroscience Reports</i> , 2018, 18, 76. | 2.0 | 29 |
| 12 | Retrospective analysis of children with myelin oligodendrocyte glycoprotein antibody-related disorders. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 26, 1-7. | 0.9 | 26 |
| 13 | Relapsing acute disseminated encephalomyelitis followed by optic neuritis in children; a clinical entity associated with anti-MOG antibody. <i>European Journal of Neurology</i> , 2018, 25, 1003-1004. | 1.7 | 1 |
| 14 | MOG-IgG-associated disease has a stereotypical clinical course, asymptomatic visual impairment and good treatment response. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2018, 4, 205521731878782. | 0.5 | 26 |
| 15 | Myelin Oligodendrocyte Glycoprotein Antibody-Positive Optic Neuritis: Clinical Characteristics, Radiologic Clues, and Outcome. <i>American Journal of Ophthalmology</i> , 2018, 195, 8-15. | 1.7 | 295 |
| 16 | MOG antibody disease: A review of MOG antibody seropositive neuromyelitis optica spectrum disorder. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 25, 66-72. | 0.9 | 158 |
| 17 | Progressive Demyelination in the Presence of Serum Myelin Oligodendrocyte Glycoprotein-IgG: A Case Report. <i>Frontiers in Neurology</i> , 2018, 9, 340. | 1.1 | 5 |
| 18 | Association of MOG-IgG Serostatus With Relapse After Acute Disseminated Encephalomyelitis and Proposed Diagnostic Criteria for MOG-IgG-Associated Disorders. <i>JAMA Neurology</i> , 2018, 75, 1355. | 4.5 | 286 |
| 19 | MOG-IgG-Associated Optic Neuritis, Encephalitis, and Myelitis: Lessons Learned From Neuromyelitis Optica Spectrum Disorder. <i>Frontiers in Neurology</i> , 2018, 9, 217. | 1.1 | 156 |
| 20 | MOG antibody disorders and AQP4 antibody NMO spectrum disorders share a common immunopathogenesis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 900-900. | 0.9 | 4 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 21 | CSF cytokine profile in MOG-IgG+ neurological disease is similar to AQP4-IgG+ NMOSD but distinct from MS: a cross-sectional study and potential therapeutic implications. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 927-936. | 0.9 | 116 |
| 22 | Clinical characteristics and prognosis of myelin oligodendrocyte glycoprotein antibody-seropositive paediatric optic neuritis in China. <i>British Journal of Ophthalmology</i> , 2019, 103, 831-836. | 2.1 | 44 |
| 23 | Different magnetic resonance imaging features between MOG antibody- and AQP4 antibody-mediated disease: A Chinese cohort study. <i>Journal of the Neurological Sciences</i> , 2019, 405, 116430. | 0.3 | 20 |
| 24 | Devic's index case: A critical reappraisal â€œ AQP4-IgG-mediated neuromyelitis optica spectrum disorder, or rather MOG encephalomyelitis?. <i>Journal of the Neurological Sciences</i> , 2019, 407, 116396. | 0.3 | 15 |
| 25 | Diagnostic Considerations in Acute Disseminated Encephalomyelitis and the Interface with MOG Antibody. <i>Neuropediatrics</i> , 2019, 50, 273-279. | 0.3 | 21 |
| 26 | Response to correspondence: Testing for myelin oligodendrocyte glycoprotein antibody (MOG-IgG) in typical MS. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 35, 156-157. | 0.9 | 0 |
| 27 | Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease. <i>Journal of Neuroinflammation</i> , 2019, 16, 134. | 3.1 | 115 |
| 28 | Identification of circulating MOG-specific B cells in patients with MOG antibodies. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, 625. | 3.1 | 44 |
| 29 | Atypical presentation of MOG-related disease: Slowly progressive behavioral and personality changes following a seizure. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 36, 101394. | 0.9 | 7 |
| 30 | Efficacy of different rituximab therapeutic strategies in patients with neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 36, 101430. | 0.9 | 23 |
| 31 | AQP4 Antibody Assay Sensitivity Comparison in the Era of the 2015 Diagnostic Criteria for NMOSD. <i>Frontiers in Neurology</i> , 2019, 10, 1028. | 1.1 | 56 |
| 32 | Autoimmune encephalomyelitis. <i>Clinical and Experimental Neuroimmunology</i> , 2019, 10, 234-243. | 0.5 | 2 |
| 33 | Therapeutic plasma exchange in children with acute demyelination. <i>Neurology</i> , 2019, 93, 953-954. | 1.5 | 0 |
| 34 | Myelin oligodendrocyte glycoprotein CSF testing needs testing. <i>Neurology</i> , 2019, 93, 871-872. | 1.5 | 4 |
| 35 | Myelin Oligodendrocyte Glycoprotein (MOG) Antibody Diseases in Children in Central South China: Clinical Features, Treatments, Influencing Factors, and Outcomes. <i>Frontiers in Neurology</i> , 2019, 10, 868. | 1.1 | 29 |
| 36 | Characterization of the human myelin oligodendrocyte glycoprotein antibody response in demyelination. <i>Acta Neuropathologica Communications</i> , 2019, 7, 145. | 2.4 | 71 |
| 37 | Treatment Approaches for MOG-Ab-Associated Demyelination in Children. <i>Current Treatment Options in Neurology</i> , 2019, 21, 2. | 0.7 | 109 |
| 38 | Visual impairment in neuromyelitis optica spectrum disorders (NMOSD). <i>Journal of Chemical Neuroanatomy</i> , 2019, 97, 66-70. | 1.0 | 6 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 39 | Incidence of pediatric neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease in Denmark 2008â€²018: A nationwide, population-based cohort study. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 33, 162-167. | 0.9 | 35 |
| 40 | Neuromyelitis Optica Spectrum Disorder and Anti-MOG Syndromes. <i>Biomedicines</i> , 2019, 7, 42. | 1.4 | 90 |
| 41 | Critical review: Typical and atypical optic neuritis. <i>Survey of Ophthalmology</i> , 2019, 64, 770-779. | 1.7 | 76 |
| 42 | MRI features of demyelinating disease associated with anti-MOG antibodies in adults. <i>Journal of Neuroradiology</i> , 2019, 46, 312-318. | 0.6 | 74 |
| 43 | MOG antibody-associated demyelinating disease mimicking typical multiple sclerosis: A case for expanding anti-MOG testing?. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 33, 67-69. | 0.9 | 10 |
| 44 | Aquaporin-4 and myelin oligodendrocyte glycoprotein antibodies in immune-mediated optic neuritis at long-term follow-up. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 1021-1026. | 0.9 | 49 |
| 45 | MOG antibody seropositive aseptic meningitis: A new clinical phenotype. <i>Journal of Neuroimmunology</i> , 2019, 333, 476960. | 1.1 | 36 |
| 46 | Different Characteristics of Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Antibody-Seropositive Male Optic Neuritis in China. <i>Journal of Ophthalmology</i> , 2019, 2019, 1-7. | 0.6 | 20 |
| 47 | Seizure and Myelin Oligodendrocyte Glycoprotein Antibody-Associated Encephalomyelitis in a Retrospective Cohort of Chinese Patients. <i>Frontiers in Neurology</i> , 2019, 10, 415. | 1.1 | 26 |
| 48 | The clinical spectrum of anti-MOG associated acquired demyelinating disorders: Three case-reports. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 33, 51-54. | 0.9 | 4 |
| 49 | Successful intravenous immunoglobulin treatment in relapsing MOG-antibody-associated disease. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 32, 27-29. | 0.9 | 18 |
| 50 | Clinical characteristics and outcomes of myelin oligodendrocyte glycoprotein antibody-seropositive optic neuritis in varying age groups: A cohort study in China. <i>Journal of the Neurological Sciences</i> , 2019, 400, 83-89. | 0.3 | 33 |
| 51 | MOG antibodyâ€“associated encephalomyelitis/encephalitis. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1427-1433. | 1.4 | 67 |
| 52 | Clinical characteristics of myelin oligodendrocyte glycoprotein antibody neuromyelitis optica spectrum disorder. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 30, 231-235. | 0.9 | 13 |
| 53 | Diagnosis and Management of Autoimmune Dementia. <i>Current Treatment Options in Neurology</i> , 2019, 21, 11. | 0.7 | 16 |
| 54 | Uveitis and optic perineuritis in the context of myelin oligodendrocyte glycoprotein antibody seropositivity. <i>European Journal of Neurology</i> , 2019, 26, 1137. | 1.7 | 33 |
| 55 | Clinical spectrum of central nervous system myelin oligodendrocyte glycoprotein autoimmunity in adults. <i>Current Opinion in Neurology</i> , 2019, 32, 459-466. | 1.8 | 38 |
| 56 | Seroprevalence and clinical phenotype of MOG-IgG-associated disorders in Sri Lanka. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, jnnp-2018-320243. | 0.9 | 23 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 57 | Clinical Characteristics and Treatment of MOG-IgG-associated Optic Neuritis. <i>Current Neurology and Neuroscience Reports</i> , 2019, 19, 100. | 2.0 | 45 |
| 58 | What You Need to Know About AQP4, MOG, and NMOSD. <i>Seminars in Neurology</i> , 2019, 39, 718-731. | 0.5 | 34 |
| 59 | Clinical and radiologic approach to "atypical" versus antibody-related optic neuritis. <i>Current Opinion in Ophthalmology</i> , 2019, 30, 412-417. | 1.3 | 11 |
| 60 | Neuromyelitis Optica: Review and Utility of Testing Aquaporin-4 Antibody in Typical Optic Neuritis. <i>Asia-Pacific Journal of Ophthalmology</i> , 2019, 7, 229-234. | 1.3 | 7 |
| 61 | Update on pediatric optic neuritis. <i>Current Opinion in Ophthalmology</i> , 2019, 30, 418-425. | 1.3 | 23 |
| 62 | Do Myelin Oligodendrocyte Glycoprotein Antibodies Represent a Distinct Syndrome?. <i>Journal of Neuro-Ophthalmology</i> , 2019, 39, 416-423. | 0.4 | 10 |
| 63 | Myelin oligodendrocyte glycoprotein antibody-associated demyelination: comparison between onset phenotypes. <i>European Journal of Neurology</i> , 2019, 26, 175-183. | 1.7 | 24 |
| 64 | Mycophenolate mofetil in paediatric autoimmune or immune-mediated diseases of the central nervous system: clinical experience and recommendations. <i>Developmental Medicine and Child Neurology</i> , 2019, 61, 458-468. | 1.1 | 15 |
| 65 | Isolated seizures during the first episode of relapsing myelin oligodendrocyte glycoprotein antibody-associated demyelination in children. <i>Developmental Medicine and Child Neurology</i> , 2019, 61, 610-614. | 1.1 | 51 |
| 66 | The widening spectrum of myelin oligodendrocyte glycoprotein antibody-associated disorders in children. <i>Developmental Medicine and Child Neurology</i> , 2019, 61, 512-513. | 1.1 | 0 |
| 67 | Follow-up study on Chinese children with relapsing MOG-IgG-associated central nervous system demyelination. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 28, 4-10. | 0.9 | 35 |
| 68 | Myelin oligodendrocyte glycoprotein antibodies in neurological disease. <i>Nature Reviews Neurology</i> , 2019, 15, 89-102. | 4.9 | 439 |
| 69 | Clinical, Radiologic, and Prognostic Features of Myelitis Associated With Myelin Oligodendrocyte Glycoprotein Autoantibody. <i>JAMA Neurology</i> , 2019, 76, 301. | 4.5 | 243 |
| 70 | Neurological update: MOG antibody disease. <i>Journal of Neurology</i> , 2019, 266, 1280-1286. | 1.8 | 171 |
| 71 | Sex differences in autoimmune disorders of the central nervous system. <i>Seminars in Immunopathology</i> , 2019, 41, 177-188. | 2.8 | 74 |
| 72 | Ocular flutter as presenting manifestation of pediatric MOG antibody-associated demyelination: A case report. <i>Multiple Sclerosis Journal</i> , 2019, 25, 122-125. | 1.4 | 9 |
| 73 | Paediatric MOG antibody-associated ADEM with complex movement disorder: A case report. <i>Multiple Sclerosis Journal</i> , 2019, 25, 125-128. | 1.4 | 12 |
| 74 | Unusual presentations of MOG antibody-associated central nervous system demyelination: Expanding the spectrum. <i>Multiple Sclerosis Journal</i> , 2019, 25, 128-129. | 1.4 | 3 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 75 | Antibodies to myelin oligodendrocyte glycoprotein in chronic relapsing inflammatory optic neuropathy. <i>British Journal of Ophthalmology</i> , 2019, 103, 1423-1428. | 2.1 | 29 |
| 76 | Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease: practical considerations. <i>Practical Neurology</i> , 2019, 19, 187-195. | 0.5 | 78 |
| 77 | The prevalence and prognostic value of myelin oligodendrocyte glycoprotein antibody in adult optic neuritis. <i>Journal of the Neurological Sciences</i> , 2019, 396, 225-231. | 0.3 | 49 |
| 78 | Mycophenolate mofetil, azathioprine and methotrexate usage in paediatric anti-NMDAR encephalitis: A systematic literature review. <i>European Journal of Paediatric Neurology</i> , 2019, 23, 7-18. | 0.7 | 17 |
| 79 | The clinical spectrum and incidence of anti-MOG-associated acquired demyelinating syndromes in children and adults. <i>Multiple Sclerosis Journal</i> , 2020, 26, 806-814. | 1.4 | 150 |
| 80 | Frequency and characteristics of short versus longitudinally extensive myelitis in adults with MOG antibodies: A retrospective multicentric study. <i>Multiple Sclerosis Journal</i> , 2020, 26, 936-944. | 1.4 | 37 |
| 81 | Relapsing lumbosacral myeloradiculitis: An unusual presentation of MOG antibody disease. <i>Multiple Sclerosis Journal</i> , 2020, 26, 509-511. | 1.4 | 34 |
| 82 | Serial Anti-Myelin Oligodendrocyte Glycoprotein Antibody Analyses and Outcomes in Children With Demyelinating Syndromes. <i>JAMA Neurology</i> , 2020, 77, 82. | 4.5 | 213 |
| 83 | Optic neuritis in the era of biomarkers. <i>Survey of Ophthalmology</i> , 2020, 65, 12-17. | 1.7 | 60 |
| 84 | Comparison of the Response to Rituximab between Myelin Oligodendrocyte Glycoprotein and Aquaporin-4 Antibody Diseases. <i>Annals of Neurology</i> , 2020, 87, 256-266. | 2.8 | 100 |
| 85 | Rituximab in children with myelin oligodendrocyte glycoprotein antibody and relapsing neuroinflammatory disease. <i>Developmental Medicine and Child Neurology</i> , 2020, 62, 390-395. | 1.1 | 20 |
| 86 | Recurrent visual loss in a 64-year-old man. <i>Practical Neurology</i> , 2020, 20, 175-178. | 0.5 | 0 |
| 87 | Deciphering anti-MOG IgG antibodies: Clinical and radiological spectrum, and comparison of antibody detection assays. <i>Journal of the Neurological Sciences</i> , 2020, 410, 116673. | 0.3 | 12 |
| 88 | Pediatric optic neuritis and anti MOG antibodies: a cohort of Italian patients. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 39, 101917. | 0.9 | 13 |
| 89 | Psychiatric Symptoms in Pediatric Patients With Myelin-Oligodendrocyte-Glycoprotein-Immunoglobulin G-Antibody Positive Autoimmune Encephalitis: A Case Series. <i>Psychosomatics</i> , 2020, 61, 846-850. | 2.5 | 3 |
| 90 | Peripheral blood helper T cell profiles and their clinical relevance in MOG-IgG-associated and AQP4-IgG-associated disorders and MS. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 132-139. | 0.9 | 20 |
| 91 | Clinical phenotype, radiological features, and treatment of myelin oligodendrocyte glycoprotein-immunoglobulin G (MOG-IgG) optic neuritis. <i>Current Opinion in Neurology</i> , 2020, 33, 47-54. | 1.8 | 80 |
| 92 | Anti-myelin oligodendrocyte glycoprotein antibody associated disease spectrum – A north Indian tertiary care centre experience and review of literature. <i>Journal of Neuroimmunology</i> , 2020, 340, 577143. | 1.1 | 14 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 93 | Brain structural and functional alterations in MOG antibody disease. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1350-1363. | 1.4 | 11 |
| 94 | Neuromyelitis optica. <i>Nature Reviews Disease Primers</i> , 2020, 6, 85. | 18.1 | 232 |
| 95 | Myelin oligodendrocyte glycoprotein antibody-positive optic neuritis with considerable white blood cell elevation in cerebrospinal fluid. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 46, 102455. | 0.9 | 4 |
| 96 | Cognitive impairment in NMOSD—More questions than answers. <i>Brain and Behavior</i> , 2020, 10, e01842. | 1.0 | 22 |
| 97 | Significance of Autoantibodies in Autoimmune Encephalitis in Relation to Antigen Localization: An Outline of Frequently Reported Autoantibodies with a Non-Systematic Review. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4941. | 1.8 | 15 |
| 98 | State of the Art and Future Challenges in Multiple Sclerosis Research and Medical Management: An Insight into the 5th International Porto Congress of Multiple Sclerosis. <i>Neurology and Therapy</i> , 2020, 9, 281-300. | 1.4 | 3 |
| 99 | Possible coexistence of MOG-IgG-associated disease and anti-Caspr2 antibody-associated autoimmune encephalitis: a first case report. <i>Therapeutic Advances in Neurological Disorders</i> , 2020, 13, 175628642096946. | 1.5 | 6 |
| 100 | E.U. paediatric MOG consortium consensus: Part 5 — Treatment of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. <i>European Journal of Paediatric Neurology</i> , 2020, 29, 41-53. | 0.7 | 59 |
| 101 | Biomarkers in Rare Demyelinating Disease of the Central Nervous System. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8409. | 1.8 | 6 |
| 102 | E.U. paediatric MOG consortium consensus: Part 4 — Outcome of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. <i>European Journal of Paediatric Neurology</i> , 2020, 29, 32-40. | 0.7 | 29 |
| 103 | Clinical and Neuroimaging Characteristics of Pediatric Acute Disseminating Encephalomyelitis With and Without Antibodies to Myelin Oligodendrocyte Glycoprotein. <i>Frontiers in Neurology</i> , 2020, 11, 593287. | 1.1 | 11 |
| 104 | E.U. paediatric MOG consortium consensus: Part 1 — Classification of clinical phenotypes of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. <i>European Journal of Paediatric Neurology</i> , 2020, 29, 2-13. | 0.7 | 87 |
| 105 | Differences in Clinical Features of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Optic Neuritis in White and Asian Race. <i>American Journal of Ophthalmology</i> , 2020, 219, 332-340. | 1.7 | 7 |
| 106 | Understanding Pediatric Neuroimmune Disorder Conflicts: A Neuroradiologic Approach in the Molecular Era. <i>Radiographics</i> , 2020, 40, 1395-1411. | 1.4 | 8 |
| 107 | Recent developments in MOG-IgG associated neurological disorders. <i>Therapeutic Advances in Neurological Disorders</i> , 2020, 13, 175628642094513. | 1.5 | 45 |
| 108 | Identification of TNFAIP3 as relapse biomarker and potential therapeutic target for MOG antibody associated diseases. <i>Scientific Reports</i> , 2020, 10, 12405. | 1.6 | 10 |
| 109 | Serum level of IL-1 β in patients with inflammatory demyelinating disease: Marked upregulation in the early acute phase of MOG antibody associated disease (MOGAD). <i>Journal of Neuroimmunology</i> , 2020, 348, 577361. | 1.1 | 14 |
| 110 | Long-term Outcomes in Patients With Myelin Oligodendrocyte Glycoprotein Immunoglobulin G-Associated Disorder. <i>JAMA Neurology</i> , 2020, 77, 1575. | 4.5 | 52 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 111 | The Expanding Clinical Spectrum of Myelin Oligodendrocyte Glycoprotein (MOG) Antibody Associated Disease in Children and Adults. <i>Frontiers in Neurology</i> , 2020, 11, 960. | 1.1 | 25 |
| 112 | Pain in NMOSD and MOGAD: A Systematic Literature Review of Pathophysiology, Symptoms, and Current Treatment Strategies. <i>Frontiers in Neurology</i> , 2020, 11, 778. | 1.1 | 37 |
| 113 | E.U. paediatric MOG consortium consensus: Part 3 – Biomarkers of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. <i>European Journal of Paediatric Neurology</i> , 2020, 29, 22-31. | 0.7 | 24 |
| 114 | Overlapping syndrome of MOG-IgG-associated disease and autoimmune GFAP astrocytopathy. <i>Journal of Neurology</i> , 2020, 267, 2589-2593. | 1.8 | 25 |
| 115 | Seizure occurrence in myelin oligodendrocyte glycoprotein antibody-associated disease: A systematic review and meta-analysis. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 42, 102057. | 0.9 | 19 |
| 116 | Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 44, 102251. | 0.9 | 110 |
| 117 | Myelin oligodendrocyte glycoprotein-associated disorders are associated with HLA subtypes in a Chinese paediatric-onset cohort. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 733-739. | 0.9 | 17 |
| 118 | Spinal Cord Involvement in MS and Other Demyelinating Diseases. <i>Biomedicines</i> , 2020, 8, 130. | 1.4 | 9 |
| 119 | Risk factors for academic difficulties in children with myelin oligodendrocyte glycoprotein antibody-associated acute demyelinating syndromes. <i>Developmental Medicine and Child Neurology</i> , 2020, 62, 1075-1081. | 1.1 | 13 |
| 120 | Acute disseminated encephalomyelitis in children and adults: A focused review emphasizing new developments. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1153-1160. | 1.4 | 22 |
| 121 | Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder. <i>Neurology</i> , 2020, 95, e111-e120. | 1.5 | 140 |
| 122 | Rituximab in patients with pediatric multiple sclerosis and other demyelinating disorders of the CNS: Practical considerations. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1814-1822. | 1.4 | 19 |
| 123 | We need to talk about MOG. <i>Neurology</i> , 2020, 95, 55-56. | 1.5 | 0 |
| 124 | Case Series: Myelin Oligodendrocyte Glycoprotein-Immunoglobulin G-Related Disease Spectrum. <i>Frontiers in Neurology</i> , 2020, 11, 89. | 1.1 | 9 |
| 125 | MOG antibody associated demyelinating syndrome presenting as aseptic meningitis in a 6-year-old boy. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 41, 102050. | 0.9 | 14 |
| 126 | First Clinical Experience with Anti-myelin Oligodendrocyte Glycoprotein Antibody-Positive Optic Neuritis. <i>Klinische Monatsblätter Für Augenheilkunde</i> , 2020, 237, 458-463. | 0.3 | 4 |
| 127 | Current and emerging biologics for the treatment of neuromyelitis optica spectrum disorders. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 1061-1072. | 1.4 | 15 |
| 128 | Acute Disseminated Encephalomyelitis followed by Optic Neuritis: A Rare Syndrome of Uncertain Treatment and Prognosis. <i>Neuropediatrics</i> , 2020, 51, 286-291. | 0.3 | 4 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 129 | Refractory case of myelin oligodendrocyte glycoprotein antibody-associated encephalomyelitis with lumbosacral radiculitis. <i>Clinical and Experimental Neuroimmunology</i> , 2020, 11, 126-130. | 0.5 | 5 |
| 130 | Effects of the Positive Threshold and Data Analysis on Human MOG Antibody Detection by Live Flow Cytometry. <i>Frontiers in Immunology</i> , 2020, 11, 119. | 2.2 | 7 |
| 131 | Atypical MOG antibody disease presenting with typical multiple sclerosis lesions. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 44, 102342. | 0.9 | 8 |
| 132 | Myelin oligodendrocyte glycoprotein antibody associated central nervous system demyelinating disease: a tertiary center experience from Turkey. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 44, 102376. | 0.9 | 8 |
| 133 | Treatment of MOG antibody associated disorders: results of an international survey. <i>Journal of Neurology</i> , 2020, 267, 3565-3577. | 1.8 | 64 |
| 134 | Serial neuropsychological testing in MOG antibody-associated disease to improve understanding of outcomes. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 44, 102316. | 0.9 | 0 |
| 135 | A unique case with positive anti-myelin oligodendrocyte glycoprotein antibody presenting multiple brain lesions. <i>Neurology and Clinical Neuroscience</i> , 2020, 8, 92-95. | 0.2 | 1 |
| 136 | Update on Pediatric Optic Neuritis. <i>Current Neurology and Neuroscience Reports</i> , 2020, 20, 4. | 2.0 | 17 |
| 137 | Clinical and immunological differences between MOG associated disease and anti AQP4 antibody-positive neuromyelitis optica spectrum disorders: Blood-brain barrier breakdown and peripheral plasmablasts. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 41, 102005. | 0.9 | 19 |
| 138 | Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study. <i>Lancet Neurology</i> , The, 2020, 19, 234-246. | 4.9 | 207 |
| 140 | MOG encephalomyelitis: distinct clinical, MRI and CSF features in patients with longitudinal extensive transverse myelitis as first clinical presentation. <i>Journal of Neurology</i> , 2020, 267, 1632-1642. | 1.8 | 24 |
| 141 | Unilateral cerebral cortical encephalitis with epilepsy: a possible special phenotype of MOG antibody-associated disorders. <i>International Journal of Neuroscience</i> , 2020, 130, 1161-1165. | 0.8 | 18 |
| 142 | Autoantibody Diagnostics in Neuroimmunology: Experience From the 2018 Italian Neuroimmunology Association External Quality Assessment Program. <i>Frontiers in Neurology</i> , 2019, 10, 1385. | 1.1 | 26 |
| 143 | Possible clinical role of MOG antibody testing in children presenting with acute neurological symptoms. <i>Neurological Sciences</i> , 2020, 41, 2553-2559. | 0.9 | 2 |
| 144 | Successful disease control with alemtuzumab in MOG-IgG-associated demyelinating disease with MS-phenotype. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 42, 102108. | 0.9 | 1 |
| 145 | Long-term efficacy of mycophenolate mofetil in myelin oligodendrocyte glycoprotein antibody-associated disorders. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, . | 3.1 | 46 |
| 146 | MOGAD: How It Differs From and Resembles Other Neuroinflammatory Disorders. <i>American Journal of Roentgenology</i> , 2021, 216, 1031-1039. | 1.0 | 44 |
| 147 | Single-cell approaches to investigate B cells and antibodies in autoimmune neurological disorders. <i>Cellular and Molecular Immunology</i> , 2021, 18, 294-306. | 4.8 | 10 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 148 | Evaluation of diagnostic criteria and red flags of myelin oligodendrocyte glycoprotein encephalomyelitis in a clinical routine cohort. <i>CNS Neuroscience and Therapeutics</i> , 2021, 27, 426-438. | 1.9 | 6 |
| 149 | Variability of cerebrospinal fluid findings by attack phenotype in myelin oligodendrocyte glycoprotein-IgG-associated disorder. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 47, 102638. | 0.9 | 20 |
| 150 | Clinical spectrum, treatment and outcome of myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease in children: a tertiary care experience. <i>Acta Neurologica Belgica</i> , 2021, 121, 231-239. | 0.5 | 6 |
| 151 | Overlapping central and peripheral nervous system syndromes in MOG antibody-associated disorders. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, . | 3.1 | 58 |
| 152 | Neuromyelitis optica spectrum disorders. <i>Journal of the Neurological Sciences</i> , 2021, 420, 117225. | 0.3 | 29 |
| 153 | Anti-MOG antibody-associated disorders: differences in clinical profiles and prognosis in Japan and Germany. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 377-383. | 0.9 | 18 |
| 154 | Myelin oligodendrocyte glycoprotein-antibody-associated disorder: a new inflammatory CNS demyelinating disorder. <i>Journal of Neurology</i> , 2021, 268, 1419-1433. | 1.8 | 26 |
| 155 | B cell depletion therapies in autoimmune disease: advances and mechanistic insights. <i>Nature Reviews Drug Discovery</i> , 2021, 20, 179-199. | 21.5 | 296 |
| 156 | Neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein associated disorder-optic neuritis: a comprehensive review of diagnosis and treatment. <i>Eye</i> , 2021, 35, 753-768. | 1.1 | 35 |
| 157 | Clinical Features and Risk of Relapse in Children and Adults with Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease. <i>Annals of Neurology</i> , 2021, 89, 30-41. | 2.8 | 123 |
| 158 | Postpartum optic neuropathy: Think of myelin oligodendrocyte glycoprotein immunoglobulin G-associated optic neuritis - Report of two cases. <i>Annals of Indian Academy of Neurology</i> , 2021, 24, 282. | 0.2 | 0 |
| 159 | Myelin Oligodendrocyte Glycoprotein (MOG) Antibody Positive Patients in a Multi-Ethnic Canadian Cohort. <i>Frontiers in Neurology</i> , 2020, 11, 525933. | 1.1 | 12 |
| 160 | Transient myelin oligodendrocyte glycoprotein antibody-positive acute disseminated encephalomyelitis following influenza A infection: A rare case. <i>Saudi Journal of Medicine and Medical Sciences</i> , 2021, 9, 271. | 0.3 | 0 |
| 161 | Immune-Mediated Disorders Affecting the Spinal Cord and the Spine. <i>Current Neurology and Neuroscience Reports</i> , 2021, 21, 3. | 2.0 | 8 |
| 162 | MOG antibody associated disorder (MOGAD). <i>Advances in Clinical Neuroscience & Rehabilitation: ACNR</i> , 0, 20, . | 0.1 | 0 |
| 163 | Validation of a Flow Cytometry Live Cell-Based Assay to Detect Myelin Oligodendrocyte Glycoprotein Antibodies for Clinical Diagnostics. <i>Journal of Applied Laboratory Medicine</i> , The, 2022, 7, 12-25. | 0.6 | 7 |
| 165 | Atypical optic neuritis: An overview. <i>Indian Journal of Ophthalmology</i> , 2021, 69, 27. | 0.5 | 10 |
| 166 | Neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein <sc>IgG</sc> associated disorder: A comprehensive neuro-ophthalmic review. <i>Clinical and Experimental Ophthalmology</i> , 2021, 49, 186-202. | 1.3 | 9 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 167 | Early age of onset predicts severity of visual impairment in patients with neuromyelitis optica spectrum disorder. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1749-1759. | 1.4 | 4 |

168 Anti-Myelin Oligodendrocyte Glycoprotein Antibody-Positive Encephalitis with Seizure and Unilateral Cortical Fluid-Attenuated Inversion Recovery-Hyperintense Lesions. *Journal of Clinical Neurology*

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 185 | Optic neuritis following SARS-CoV-2 infection. <i>Journal of NeuroVirology</i> , 2021, 27, 359-363. | 1.0 | 27 |
| 187 | New Therapeutic Landscape in Neuromyelitis Optica. <i>Current Treatment Options in Neurology</i> , 2021, 23, 13. | 0.7 | 11 |
| 188 | Drug Treatment of Neuromyelitis Optica Spectrum Disorders: Out with the Old, in with the New?. <i>ImmunoTargets and Therapy</i> , 2021, Volume 10, 87-101. | 2.7 | 15 |
| 189 | MOG-IgG Associated Disease (MOG-AD) in Adults. <i>Current Treatment Options in Neurology</i> , 2021, 23, 1. | 0.7 | 1 |
| 190 | Myelin Oligodendrocyte Glycoprotein Antibody-Associated Optic Neuritis—A Review. <i>Journal of Neuro-Ophthalmology</i> , 2021, Publish Ahead of Print, e786-e795. | 0.4 | 0 |
| 191 | Comparative analysis of immunosuppressive therapies for myelin oligodendrocyte glycoprotein antibody-associated optic neuritis: a cohort study. <i>British Journal of Ophthalmology</i> , 2022, 106, 1587-1595. | 2.1 | 8 |
| 192 | New-onset epilepsy in a patient with myelin oligodendrocyte glycoprotein antibodies. <i>Encephalitis</i> , 2021, 1, 56-59. | 0.3 | 1 |
| 193 | Frequency of myelin oligodendrocyte glycoprotein antibodies in a large cohort of neurological patients. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2021, 7, 205521732110227. | 0.5 | 20 |
| 194 | Emerging drugs for the treatment of adult MOG-IgG-associated diseases. <i>Expert Opinion on Emerging Drugs</i> , 2021, 26, 75-78. | 1.0 | 11 |
| 195 | Antibody-Mediated Encephalitis in Children: Focus on Diagnostic Clues and Acute Symptom Management. <i>Seminars in Pediatric Neurology</i> , 2021, 37, 100873. | 1.0 | 3 |
| 196 | Update on Acute Disseminated Encephalomyelitis in Children and Adolescents. <i>Children</i> , 2021, 8, 280. | 0.6 | 20 |
| 197 | Immune-Mediated Myelopathies: A Review of Etiologies, Diagnostic Approach, and Therapeutic Management. <i>Seminars in Neurology</i> , 2021, 41, 269-279. | 0.5 | 2 |
| 198 | Clinical and neuroimaging characteristics of MOG autoimmunity in children with acquired demyelinating syndromes. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 50, 102837. | 0.9 | 7 |
| 199 | Age-dependent favorable visual recovery despite significant retinal atrophy in pediatric MOGAD: how much retina do you really need to see well?. <i>Journal of Neuroinflammation</i> , 2021, 18, 121. | 3.1 | 22 |
| 200 | Anti-MOG antibody associated long segment myelitis presenting as anterior cord syndrome. <i>BMJ Case Reports</i> , 2021, 14, e240055. | 0.2 | 0 |
| 201 | Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: Presentation, Diagnosis, and Management. <i>Pediatric Annals</i> , 2021, 50, e254-e258. | 0.3 | 2 |
| 202 | A nation-wide survey of Japanese pediatric MOG antibody-associated diseases. <i>Brain and Development</i> , 2021, 43, 705-713. | 0.6 | 7 |
| 203 | Case Report: Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disorder Masquerading as Multiple Sclerosis: An Under-Recognized Entity?. <i>Frontiers in Immunology</i> , 2021, 12, 671425. | 2.2 | 5 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 204 | The diagnostic dilemma of bilateral optic neuritis and idiopathic intracranial hypertension coexistence in a patient with recent COVID-19 infection. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, e04347. | 0.2 | 16 |
| 205 | Clinical and neuroimaging findings in MOGAD—MRI and OCT. <i>Clinical and Experimental Immunology</i> , 2021, 206, 266-281. | 1.1 | 24 |
| 206 | Clinical experience of plasmapheresis for neuromyelitis optica patients in Mexico. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 52, 103022. | 0.9 | 4 |
| 207 | Epstein-Barr virus-associated acute disseminated encephalomyelitis successfully treated with rituximab: a case report. <i>Encephalitis</i> , 2021, 1, 85-88. | 0.3 | 4 |
| 208 | Assessing attacks and treatment response rates among adult patients with NMOSD and MOGAD: Data from a nationwide registry in Argentina. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2021, 7, 20552173211032334. | 0.5 | 4 |
| 209 | Overlapping syndrome of anti-N-methyl-D-aspartate receptor encephalitis and anti-myelin oligodendrocyte glycoprotein inflammatory demyelinating diseases: A distinct clinical entity?. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 52, 103020. | 0.9 | 9 |
| 210 | Comparison of MRI Lesion Evolution in Different Central Nervous System Demyelinating Disorders. <i>Neurology</i> , 2021, 97, e1097-e1109. | 1.5 | 77 |
| 211 | Clinical Features of Coexisting Anti-NMDAR and MOG Antibody-Associated Encephalitis: A Systematic Review and Meta-Analysis. <i>Frontiers in Neurology</i> , 2021, 12, 711376. | 1.1 | 17 |
| 212 | Acute Demyelinating Syndrome (MOG Antibody Positive) Associated With COVID-19 Infection: A Widening spectrum. <i>Clinical Pediatrics</i> , 2021, 60, 501-503. | 0.4 | 11 |
| 213 | Tumefactive demyelination: updated perspectives on diagnosis and management. <i>Expert Review of Neurotherapeutics</i> , 2021, 21, 1005-1017. | 1.4 | 5 |
| 214 | At this Junction— . <i>Survey of Ophthalmology</i> , 2021, , . | 1.7 | 0 |
| 215 | Safety and efficacy of mycophenolate mofetil in myelin oligodendrocyte glycoprotein—immunoglobulin—associated disorder among adults: A meta—analysis. <i>Clinical and Experimental Neuroimmunology</i> , 0, , . | 0.5 | 0 |
| 216 | A comparison of the effects of rituximab versus other immunotherapies for MOG-IgG-associated central nervous system demyelination: A meta-analysis. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 53, 103044. | 0.9 | 2 |
| 217 | Differential efficacy of mycophenolate mofetil in adults with relapsing myelin oligodendrocyte glycoprotein antibody-associated disorders. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 53, 103035. | 0.9 | 8 |
| 218 | The occurrence of myelin oligodendrocyte glycoprotein antibodies in aquaporin-4-antibody seronegative Neuromyelitis Optica Spectrum Disorder: A systematic review and meta-analysis. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 53, 103030. | 0.9 | 12 |
| 219 | Aseptic meningitis and leptomeningeal enhancement associated with anti-MOG antibodies: A review. <i>Journal of Neuroimmunology</i> , 2021, 358, 577653. | 1.1 | 18 |
| 220 | Clinical decision making in MOG antibody-associated disease. <i>Lancet Neurology</i> , The, 2021, 20, 695-697. | 4.9 | 3 |
| 221 | Myelin-oligodendrocyte glycoprotein antibody-associated disease. <i>Lancet Neurology</i> , The, 2021, 20, 762-772. | 4.9 | 261 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 222 | Overlapping syndrome mimicking infectious meningoencephalitis in a patient with MOG and GFAP IgG. <i>BMC Neurology</i> , 2021, 21, 348. | 0.8 | 8 |
| 223 | Retinal optical coherence tomography and magnetic resonance imaging in neuromyelitis optica spectrum disorders and MOG-antibody associated disorders: an updated review. <i>Expert Review of Neurotherapeutics</i> , 2021, 21, 1101-1123. | 1.4 | 7 |
| 224 | Myelin oligodendrocyte glycoprotein (MOG) antibody-mediated disease: The difficulty of predicting relapses. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 56, 103229. | 0.9 | 16 |
| 225 | Seizures in myelin oligodendrocyte glycoprotein antibody-associated disorders and related immune factors. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2021, 92, 216-220. | 0.9 | 8 |
| 226 | Evidence for and against subclinical disease activity and progressive disease in MOG antibody disease and neuromyelitis optica spectrum disorder. <i>Journal of Neuroimmunology</i> , 2021, 360, 577702. | 1.1 | 13 |
| 227 | Optic neuritis in Asian type opticospinal multiple sclerosis (OSMS-ON) in a non-Asian population: A functional-structural paradox. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 56, 103260. | 0.9 | 2 |
| 228 | Clinical characteristics, disease course, and outcomes of paediatric patients with myelin oligodendrocyte glycoprotein-Ab associated disease: A retrospective clinical study. <i>Journal of Clinical Neuroscience</i> , 2021, 94, 1-7. | 0.8 | 2 |
| 229 | Clinical Approach to Autoimmune and Inflammatory Ophthalmologic Disease. , 2021, , 447-467. | | 0 |
| 230 | Transient tunnel vision as initial presentation of anti-MOG antibody positive optic neuritis. <i>Annals of Indian Academy of Neurology</i> , 2021, 24, 456. | 0.2 | 0 |
| 232 | Age-Related Clinical Presentation of MOG-IgG Seropositivity in Israel. <i>Frontiers in Neurology</i> , 2020, 11, 612304. | 1.1 | 11 |
| 233 | The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody. <i>Acta Neuropathologica</i> , 2020, 139, 875-892. | 3.9 | 205 |
| 234 | Efficacy and safety of long-term immunotherapy in adult patients with MOG antibody disease: a systematic analysis. <i>Journal of Neurology</i> , 2021, 268, 4537-4548. | 1.8 | 13 |
| 236 | MRI Characteristics of NMO, MOG and MS Related Optic Neuritis. <i>Seminars in Ophthalmology</i> , 2020, 35, 333-342. | 0.8 | 25 |
| 237 | Pediatric Central Nervous System Demyelinating Diseases. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2019, 25, 793-814. | 0.4 | 9 |
| 239 | Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: Current Insights into the Disease Pathophysiology, Diagnosis and Management. <i>International Journal of Molecular Sciences</i> , 2021, 22, 100. | 1.8 | 74 |
| 240 | MOG Antibody-Associated Disease with Recurrent Optic Neuritis and Multiple Cranial Neuropathies: A Rare Clinical Phenotype. <i>Neurology India</i> , 2020, 68, 500. | 0.2 | 4 |
| 241 | Case Report: Postvaccination Anti-Myelin Oligodendrocyte Glycoprotein Neuromyelitis Optica Spectrum Disorder. <i>International Journal of MS Care</i> , 2020, 22, 85-90. | 0.4 | 32 |
| 242 | Comparison of Spinal Cord Magnetic Resonance Imaging Features Among Children With Acquired Demyelinating Syndromes. <i>JAMA Network Open</i> , 2021, 4, e2128871. | 2.8 | 27 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 243 | Meta-analysis of effectiveness of steroid-sparing attack prevention in MOG-IgG-associated disorder. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 56, 103310. | 0.9 | 9 |
| 244 | Myelin oligodendrocyte glycoprotein (MOG) antibodies in a patient with glioblastoma: Red flags for false positivity. <i>Journal of Neuroimmunology</i> , 2021, 361, 577743. | 1.1 | 7 |
| 245 | Clinicoradiological comparative study of Aquaporin-4-IgG seropositive neuromyelitis optica spectrum disorder (NMOSD) and MOG antibody associated disease (MOGAD): A prospective observational study and review of literature. <i>Journal of Neuroimmunology</i> , 2021, 361, 577742. | 1.1 | 8 |
| 246 | Uncommon inflammatory/immune-related myelopathies. <i>Journal of Neuroimmunology</i> , 2021, 361, 577750. | 1.1 | 4 |
| 247 | Recurrent Optic Neuritis and Acute Encephalopathy with Myelin Oligodendrocyte Glycoprotein Antibodies in a Korean Child. <i>Soonchunhyang Medical Science</i> , 2019, 25, 121-124. | 0.0 | 0 |
| 248 | The neuromyelitis optica spectrum disorders. <i>Neurologie Pro Praxi</i> , 2019, 20, 368-372. | 0.0 | 0 |
| 249 | Hope for patients with neuromyelitis optica spectrum disorders “ from mechanisms to trials. <i>Nature Reviews Neurology</i> , 2021, 17, 759-773. | 4.9 | 57 |
| 250 | GRP78 Antibodies Are Associated With Blood-Brain Barrier Breakdown in Anti“ Myelin Oligodendrocyte Glycoprotein Antibody“ Associated Disorder. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, . | 3.1 | 15 |
| 251 | Post-infectious Encephalomyelitis. <i>Current Clinical Neurology</i> , 2021, , 305-321. | 0.1 | 0 |
| 252 | Anti-MOG Diseases. , 2020, , 95-108. | | 0 |
| 253 | Diagnostic features of initial demyelinating events associated with serum MOG-IgG. <i>Journal of Neuroimmunology</i> , 2020, 344, 577260. | 1.1 | 0 |
| 255 | A case of bilateral limbic and recurrent unilateral cortical encephalitis with anti-myelin oligodendrocyte glycoprotein antibody positivity. <i>Brain and Development</i> , 2022, 44, 254-258. | 0.6 | 1 |
| 256 | Predictors of relapse in MOG antibody associated disease: a cohort study. <i>BMJ Open</i> , 2021, 11, e055392. | 0.8 | 30 |
| 257 | Efficacy and safety of immunosuppressive therapy in myelin oligodendrocyte glycoprotein antibody“ associated disease: a systematic review and meta-analysis. <i>Therapeutic Advances in Neurological Disorders</i> , 2021, 14, 175628642110541. | 1.5 | 7 |
| 258 | OCT retinal nerve fiber layer thickness differentiates acute optic neuritis from MOG antibody-associated disease and Multiple Sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 58, 103525. | 0.9 | 36 |
| 259 | Factors Associated With Relapse and Treatment of Myelin Oligodendrocyte Glycoprotein Antibody“ Associated Disease in the United Kingdom. <i>JAMA Network Open</i> , 2022, 5, e2142780. | 2.8 | 46 |
| 260 | Structural and functional markers of optic nerve damage in myelin oligodendrocyte glycoprotein antibody-associated optic neuritis. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2021, 7, 205521732110631. | 0.5 | 5 |
| 261 | Treatment of myelin oligodendrocyte glycoprotein antibody associated disease with subcutaneous immune globulin. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 57, 103462. | 0.9 | 10 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 262 | Acute Disseminated Encephalomyelitis and Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease. , 2022, , 290-314. | | 0 |
| 263 | Clinico-radiological characteristics of anti-myelin oligodendrocyte glycoprotein antibody-associated autoimmune encephalitis in children. <i>Developmental Medicine and Child Neurology</i> , 2022, 64, 998-1007. | 1.1 | 5 |
| 264 | Clinical analysis of myelin oligodendrocyte glycoprotein antibody-associated demyelination in children: A single-center cohort study in China. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 58, 103526. | 0.9 | 3 |
| 265 | Safety and efficacy of rituximab for relapse prevention in myelin oligodendrocyte glycoprotein immunoglobulin G (MOG-IgG)-associated disorders (MOGAD): A systematic review and meta-analysis. <i>Journal of Neuroimmunology</i> , 2022, 364, 577812. | 1.1 | 18 |
| 266 | CLINICAL CASE OF NEUROMYELITIS OPTICA SPECTRUM DISORDERS IN YOUNG WOMAN TREATED WITH RITUXIMAB. <i>Wiadomości Lekarskie</i> , 2022, 75, 132-137. | 0.1 | 1 |
| 268 | Demyelinating Diseases of the Central Nervous System and Seizures. <i>Advances in Clinical Medicine</i> , 2022, 12, 2329-2333. | 0.0 | 0 |
| 269 | Pediatric acute disseminated encephalomyelitis associated with myelin oligodendrocyte glycoprotein antibodies. <i>Srpski Arhiv Za Celokupno Lekarstvo</i> , 2022, 150, 212-215. | 0.1 | 0 |
| 270 | Volumetric Brain Loss Correlates With a Relapsing MOGAD Disease Course. <i>Frontiers in Neurology</i> , 2022, 13, 867190. | 1.1 | 12 |
| 271 | Serum neurofilament light-chain levels in children with monophasic myelin oligodendrocyte glycoprotein-associated disease, multiple sclerosis, and other acquired demyelinating syndrome. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1553-1561. | 1.4 | 20 |
| 272 | Magnetic Resonance Imaging of Autoimmune Demyelinating Diseases as a Diagnostic Challenge for Radiologists: Report of Two Cases and Literature Review. <i>Life</i> , 2022, 12, 488. | 1.1 | 0 |
| 273 | Failure of alemtuzumab therapy in three patients with MOG antibody associated disease. <i>BMC Neurology</i> , 2022, 22, 84. | 0.8 | 3 |
| 274 | Monoclonal Antibody Therapies Beyond Complement for NMOSD and MOGAD. <i>Neurotherapeutics</i> , 2022, 19, 808-822. | 2.1 | 14 |
| 275 | Mesenchymal Stem Cell-Derived Extracellular Vesicles and Their Therapeutic Use in Central Nervous System Demyelinating Disorders. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3829. | 1.8 | 7 |
| 276 | MOG antibody disease with ovarian teratoma: A case report and review of the literature. <i>Journal of Neuroimmunology</i> , 2022, 367, 577858. | 1.1 | 2 |
| 277 | Clinical Features and Imaging Findings of Myelin Oligodendrocyte Glycoprotein-IgG-Associated Disorder (MOGAD). <i>Frontiers in Aging Neuroscience</i> , 2022, 14, 850743. | 1.7 | 7 |
| 278 | Clinical characteristics and clinical course of myelin oligodendrocyte glycoprotein antibody-seropositive pediatric optic neuritis. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 60, 103709. | 0.9 | 5 |
| 279 | Clinical Profile and Treatment Outcome in MOGAD: A Single-Center Case-Series Study in Guiyang, China. <i>Frontiers in Neurology</i> , 2022, 13, 830488. | 1.1 | 3 |
| 280 | Association of Maintenance Intravenous Immunoglobulin With Prevention of Relapse in Adult Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease. <i>JAMA Neurology</i> , 2022, 79, 518. | 4.5 | 39 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 281 | Efficacy of Plasma Exchange Treatment for Demyelinating Optic Neuritis Associated with Various Serum Antibodies: A Prospective Cohort Study. <i>Neurology and Therapy</i> , 2022, 11, 797-813. | 1.4 | 3 |
| 282 | Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-IgG-Associated Disease and Neuromyelitis Optica Spectrum Disorders. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, . | 3.1 | 64 |
| 283 | Subtotal hemispherotomy for late-onset spasms after anti-myelin oligodendrocyte glycoprotein antibody-positive acute haemorrhagic leukoencephalitis. <i>Epileptic Disorders</i> , 2021, 23, 957-960. | 0.7 | 4 |
| 284 | Influential Factors and Predictors of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease Related to Severity in the First Episode. <i>SSRN Electronic Journal</i> , 0, , . | 0.4 | 0 |
| 285 | Pain Symptoms in Optic Neuritis. <i>Frontiers in Pain Research</i> , 2022, 3, 865032. | 0.9 | 4 |
| 292 | FLAMES with Elevated Myelin Basic Protein Followed by Myelitis. <i>Internal Medicine</i> , 2022, 61, 3585-3588. | 0.3 | 3 |
| 294 | Optic Neuritis in the Era of NMOSD and MOGAD: A Survey of Practice Patterns in Singapore. <i>Asia-Pacific Journal of Ophthalmology</i> , 2022, 11, 184-195. | 1.3 | 4 |
| 295 | Rare nervous system involvement in an anti-myelin oligodendrocyte-positive case: spinal leptomeningeal involvement. <i>Journal of Surgery and Medicine</i> , 2022, 6, 1-1. | 0.0 | 0 |
| 296 | Myelin oligodendrocyte glycoprotein antibody-associated bilateral optic neuritis with unilateral prepapillary vitreous hemorrhage. <i>Journal of AAPOS</i> , 2022, , . | 0.2 | 0 |
| 297 | COVID-19 Vaccine- A Potential Trigger for MOGAD Transverse Myelitis in a Teenager- A Case Report and a Review of the Literature. <i>Children</i> , 2022, 9, 674. | 0.6 | 4 |
| 298 | Optic neuritis with potential for poor outcome. <i>Practical Neurology</i> , 2022, , practneurol-2021-003228. | 0.5 | 0 |
| 299 | Comparison of neutrophil-to-lymphocyte ratio between myelin oligodendrocyte glycoprotein antibody-associated disease and aquaporin-4 antibody-positive neuromyelitis optica spectrum disorders in adults. <i>Journal of Clinical Neuroscience</i> , 2022, 101, 89-93. | 0.8 | 3 |
| 300 | Rare autoimmune encephalitis presenting as fluid-attenuated inversion recovery-hyperintense lesions in anti-Myelin oligodendrocyte glycoprotein-associated encephalitis and seizures accompanied with anti-IgLON5 antibody. <i>Quantitative Imaging in Medicine and Surgery</i> , 2021, . | 1.1 | 2 |
| 301 | Clinical and Radiological Features of Myelin Oligodendrocyte Glycoprotein-Associated Myelitis in | | |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 306 | MOG encephalomyelitis after vaccination against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2): case report and comprehensive review of the literature. <i>Journal of Neurology</i> , 2022, 269, 5198-5212. | 1.8 | 32 |
| 307 | Pathomechanisms in demyelination and astrocytopathy: autoantibodies to AQP4, MOG, GFAP, GRP78 and beyond. <i>Current Opinion in Neurology</i> , 2022, 35, 427-435. | 1.8 | 3 |
| 308 | Immunotherapy in autoimmune encephalitis. <i>Current Opinion in Neurology</i> , 2022, 35, 399-414. | 1.8 | 11 |
| 309 | A case of unilateral recurrent cerebral cortical encephalitis with anti-myelin oligodendrocyte glycoprotein antibodies. <i>Brain Circulation</i> , 2022, 8, 102. | 0.7 | 1 |
| 310 | Neuromyelitis optica spectrum disorders and anti-myelin oligodendrocyte glycoprotein positive optic neuropathies. <i>International Journal of Ophthalmology</i> , 2022, 15, 1095-1107. | 0.5 | 0 |
| 311 | Case report: A patient with meningoencephalitis followed by asymptomatic anti-myelin oligodendrocyte glycoprotein antibody-related disorder. <i>Journal of Neurorestoratology</i> , 2022, 10, 100007. | 1.1 | 0 |
| 312 | Effectiveness and tolerability of different therapies in preventive treatment of MOG-IgG-associated disorder: A network meta-analysis. <i>Frontiers in Immunology</i> , 0, 13, . | 2.2 | 2 |
| 313 | Update on glial antibody-mediated optic neuritis. <i>Japanese Journal of Ophthalmology</i> , 2022, 66, 405-412. | 0.9 | 2 |
| 314 | The role of complement and complement therapeutics in neuromyelitis optica spectrum disorders. <i>Expert Review of Clinical Immunology</i> , 2022, 18, 933-945. | 1.3 | 6 |
| 315 | A 24-Year-Old Woman Presenting with Decreased Visual Acuity and Pain on Left Eye. <i>Journal of the Korean Neurological Association</i> , 2022, 40, 280-286. | 0.0 | 0 |
| 316 | Steroidâ€responsive aseptic meningitis with raised intracranial pressure syndrome associated with myelin oligodendrocyte glycoprotein autoantibodies. <i>Journal of Paediatrics and Child Health</i> , 2022, 58, 2322-2326. | 0.4 | 1 |
| 317 | Mycophenolate mofetil: An alternative disease-modifying agent for MOG-IgG-associated disorders in childhood: A single-center bidirectional cohort study. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 68, 104128. | 0.9 | 1 |
| 318 | Myelin Oligodendrocyte Glycoproteinâ€Associated Disorders. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2022, 28, 1171-1193. | 0.4 | 4 |
| 319 | Encephalitis with Extensive Cortical Brain Magnetic Resonance Imaging Changes Secondary to Myelin Oligodendrocyte Glycoprotein Antibody Disease. <i>American Journal of Case Reports</i> , 0, 23, . | 0.3 | 0 |
| 320 | The Treatment of Myelin Oligodendrocyte Glycoprotein Antibody Disease: A State-of-the-Art Review. <i>Journal of Neuro-Ophthalmology</i> , 2022, 42, 292-296. | 0.4 | 3 |
| 321 | Myelin oligodendrocyte glycoprotein associated transverse myelitis following brain abscess: Case report and literature review. <i>Journal of Neuroimmunology</i> , 2022, 372, 577967. | 1.1 | 1 |
| 322 | Treatment and Relapse Prevention of Typical and Atypical Optic Neuritis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 9769. | 1.8 | 8 |
| 323 | Long-term Effectiveness and Safety of Rituximab in Neuromyelitis Optica Spectrum Disorder and MOG Antibody Disease. <i>Neurology</i> , 2022, 99, . | 1.5 | 22 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 324 | The Prevalence, Demographics, Clinical Features, Neuroimaging, and Inter-ethnic Differences of MOGAD in Malaysia with Global Perspectives. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 67, 104168. | 0.9 | 5 |
| 325 | Optic neuritis and autoimmune optic neuropathies: advances in diagnosis and treatment. <i>Lancet Neurology</i> , The, 2023, 22, 89-100. | 4.9 | 53 |
| 326 | Acute symptomatic seizures secondary to myelin oligodendrocyte glycoprotein antibody-associated disease. <i>Epilepsia</i> , 2022, 63, 3180-3191. | 2.6 | 8 |
| 327 | Temporal Dynamics of MOG Antibodies in Children With Acquired Demyelinating Syndrome. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, . | 3.1 | 20 |
| 328 | Efficacy and safety of rituximab in myelin oligodendrocyte glycoprotein antibody-associated disorders compared with neuromyelitis optica spectrum disorder: a systematic review and meta-analysis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2023, 94, 62-69. | 0.9 | 7 |
| 329 | MOG antibody-associated encephalitis in adult: clinical phenotypes and outcomes. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2023, 94, 102-112. | 0.9 | 9 |
| 330 | Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease Presenting as Intracranial Hypertension. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, . | 3.1 | 7 |
| 331 | Autoimmune diseases and cancers overlapping with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): A systematic review. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2022, 8, 205521732211281. | 0.5 | 3 |
| 332 | Details and outcomes of a large cohort of MOG-IgG associated optic neuritis. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 68, 104237. | 0.9 | 15 |
| 333 | Targeting B cell dysregulation with emerging therapies in autoimmune demyelinating disorders. <i>Current Opinion in Neurobiology</i> , 2022, 77, 102643. | 2.0 | 0 |
| 334 | Immune-mediated and autoimmune disorders of central nervous system after new coronavirus disease. <i>IzvestiĀ Rossijskoj Voenno-meditsinskoj Akademii</i> , 2022, 41, 445-453. | 0.1 | 0 |
| 335 | Early Immunotherapy and Longer Corticosteroid Treatment Are Associated With Lower Risk of Relapsing Disease Course in Pediatric MOGAD. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2023, 10, . | 3.1 | 14 |
| 336 | Serial analyses of clinical spectra and outcomes in Chinese women with pregnancy-induced optic neuritis. <i>Frontiers in Medicine</i> , 0, 9, . | 1.2 | 1 |
| 337 | Acute Inflammatory Diseases of the Central Nervous System After SARS-CoV-2 Vaccination. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2023, 10, . | 3.1 | 24 |
| 338 | Myelin oligodendrocyte glycoprotein (MOG) antibody-associated longitudinally extensive transverse myelitis (LETM) and primary Sjogren syndrome: a rare association. <i>BMJ Case Reports</i> , 2022, 15, e249915. | 0.2 | 1 |
| 339 | Time to steroids impacts visual outcome of optic neuritis in MOGAD. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2023, 94, 309-313. | 0.9 | 7 |
| 340 | <sc>Non-AD–EM</sc> encephalitis in patients with myelin oligodendrocyte glycoprotein antibodies: a systematic review. <i>European Journal of Neurology</i> , 2023, 30, 1515-1527. | 1.7 | 6 |
| 341 | <sc>MOG</sc> antibody associated with central and peripheral demyelination. <i>Progress in Neurology and Psychiatry</i> , 2023, 27, 12-15. | 0.4 | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 342 | Research Progress of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Optic Neuritis. <i>Advances in Clinical Medicine</i> , 2023, 13, 4853-4859. | 0.0 | 0 |
| 343 | Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. <i>Lancet Neurology</i> , The, 2023, 22, 268-282. | 4.9 | 250 |
| 344 | Complement-dependent cytotoxicity of human autoantibodies against myelin oligodendrocyte glycoprotein. <i>Frontiers in Neuroscience</i> , 0, 17, . | 1.4 | 3 |
| 346 | A case of anti-myelin oligodendrocyte glycoprotein (MOG)-immunoglobulin G (IgG) associated disorder (MOGAD) with clinical manifestations of acute disseminated encephalomyelitis: Secondary to <i>Mycoplasma pneumoniae</i> infection. <i>Heliyon</i> , 2023, 9, e13470. | 1.4 | 2 |
| 347 | Meta-analysis of the effectiveness of relapse prevention therapy for myelin-oligodendrocyte glycoprotein antibody-associated disease. <i>Multiple Sclerosis and Related Disorders</i> , 2023, 72, 104571. | 0.9 | 4 |
| 348 | Origins and immunopathogenesis of autoimmune central nervous system disorders. <i>Nature Reviews Neurology</i> , 2023, 19, 172-190. | 4.9 | 9 |
| 349 | The Acute Optic Neuritis Network (ACON): Study protocol of a non-interventional prospective multicenter study on diagnosis and treatment of acute optic neuritis. <i>Frontiers in Neurology</i> , 0, 14, . | 1.1 | 4 |
| 350 | A Case of Transverse Myelitis After Moderna Severe Acute Respiratory Syndrome Coronavirus Vaccination. <i>Neurohospitalist</i> , The, 2023, 13, 192-195. | 0.3 | 2 |
| 351 | Low mortality rate in a large cohort of myelin oligodendrocyte glycoprotein antibody disease (<scp>MOGAD</scp>). <i>Annals of Clinical and Translational Neurology</i> , 2023, 10, 664-667. | 1.7 | 2 |
| 352 | Pathophysiology of myelin oligodendrocyte glycoprotein antibody disease. <i>Frontiers in Neurology</i> , 0, 14, . | 1.1 | 10 |
| 353 | B cell targeted therapies in inflammatory autoimmune disease of the central nervous system. <i>Frontiers in Immunology</i> , 0, 14, . | 2.2 | 7 |
| 354 | Multiple types of relapses in MOG antibody disease. <i>Multiple Sclerosis and Related Disorders</i> , 2023, 72, 104613. | 0.9 | 3 |
| 355 | The neuro-ophthalmological manifestations of NMOSD and MOGADâ€™a comprehensive review. <i>Eye</i> , 2023, 37, 2391-2398. | 1.1 | 3 |
| 356 | Attack phenotypes and disease course in pediatric <scp>MOGAD</scp>. <i>Annals of Clinical and Translational Neurology</i> , 0, , . | 1.7 | 0 |
| 358 | Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD)â€™ revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis. <i>Journal of Neurology</i> , 2023, 270, 3341-3368. | 1.8 | 23 |
| 359 | Current perspectives on the diagnosis and management of acute transverse myelitis. <i>Expert Review of Neurotherapeutics</i> , 2023, 23, 389-411. | 1.4 | 2 |
| 360 | Myelin Oligodendrocyte Glycoprotein as an Autoantigen in Inflammatory Demyelinating Diseases of the Central Nervous System. <i>Biochemistry (Moscow)</i> , 2023, 88, 551-563. | 0.7 | 1 |
| 361 | Can volumetric analysis of the brain help diagnose isolated optic neuritis?. <i>Clinical Anatomy</i> , 2023, 36, 1109-1115. | 1.5 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 387 | Pediatric Multiple Sclerosis: Changing the Trajectory of Progression. Current Neurology and Neuroscience Reports, 0, , . | 2.0 | 1 |
| 401 | Myelin Oligodendrocyte Glycoprotein Antibody Associated Disease. , 2024, , . | | 0 |